Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ModernaCHIX:0QFD 65 Gross Margin % is 35.86% as of Jun. 2026, which is 43% below its 10-year median of 63.08. GuruFocus rates CHIX:0QFD with a GF Score™ of 65/100 and a GF Value™ of €31.22 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 734 Biotechnology companies, Moderna ranks worse than 81.34% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Moderna's Gross Profit for the
three
months ended in Jun. 2026 was €45 Mil. Moderna's Revenue for the
three
months ended in Jun. 2026 was €126 Mil. Therefore, Moderna's Gross Margin % for the quarter that ended in Jun. 2026 was 35.86%.
Warning Sign:
Moderna Inc gross margin has been in long-term decline. The average rate of decline per year is -13.5%.
The historical rank and industry rank for Moderna's Gross Margin % or its related term are showing as below:
CHIX:0QFd'
s Gross Margin % Range Over the Past 10 Years
Min: 22.83 Med: 63.08 Max: 97.08
Current: 22.83
During the past 10 years, the highestGross Margin % of Moderna was 97.08%. The lowest was 22.83%. And the median was 63.08%.
CHIX:0QFd's Gross Margin % is ranked worse than 81.34% of 734
companies
in the Biotechnology industry
Industry Median: 60.905
vs CHIX:0QFd: 22.83
Moderna had a gross margin of 35.86% for the quarter that ended in Jun. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Moderna was -13.50% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Moderna had a gross margin of 35.86% for the quarter that ended in Jun. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Moderna Gross Margin % Related Terms
Moderna Gross Margin % Historical Data
* Premium members only.
The historical data trend for Moderna's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:0QFD vs BNTX, INSM, INCY: Gross Margin % Comparison
For the Biotechnology subindustry, Moderna's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moderna Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moderna's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Moderna's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Moderna (CHIX:0QFD) has a Gross Margin % of 35.86% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Moderna and its competitors. This is 43% below median its historical median of 63.08. Over the past decade, Moderna's Gross Margin % has ranged from 22.83 to 97.08. According to the industry distribution chart, Moderna ranks #597 out of 734 companies in the Biotechnology industry, placing it in the top 81.3%.
Is Moderna's Gross Margin % too high?
Moderna's current Gross Margin % of 35.86% is 43% below median its 10-year median of 63.08. Over the past 10 years, this metric has ranged from a low of 22.83 to a high of 97.08. The Biotechnology industry median Gross Margin % is 60.91. Moderna's value of 35.86% is 41.1% below this industry median. Based on the distribution chart, Moderna ranks #597 out of 734 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Moderna has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Moderna's Gross Margin % compare to BNTX and INSM?
According to the Biotechnology industry distribution chart, Moderna ranks #597 out of 734 companies for Gross Margin %. This places Moderna in the lower half of its industry. The industry median Gross Margin % is 60.91. Moderna's value of 35.86% is 41.1% below this benchmark. Historically, Moderna's own Gross Margin % has ranged from 22.83 to 97.08 over the past decade. While the company's 10-year median is 63.08 vs. the industry median of 60.91, Moderna has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moderna's current Gross Margin % of 35.86% is 41.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Moderna and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moderna's current Gross Margin % is 35.86%, which is 43% below median its own 10-year median of 63.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moderna stock overvalued right now?
Based on GuruFocus' analysis, Moderna (CHIX:0QFD) is currently considered Significantly Overvalued. The stock's GF Value™ is €31.22, compared to a current price of €70.49 — trading 125.8% above its estimated fair value. The current Gross Margin % is 35.86%, which is 43% below median its 10-year median of 63.08 and 41.1% below the Biotechnology industry median of 60.91. Moderna's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Moderna (CHIX:0QFD), the current Gross Margin % is 35.86% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moderna (CHIX:0QFD) Overvalued in 2026?
Based on GuruFocus' analysis, Moderna stock appears to be overvalued.
The current stock price of €70.49 is trading 125.8% above its estimated GF Value™ of €31.22.
GuruFocus considers Moderna to be Significantly Overvalued.
Key valuation signals for CHIX:0QFD:
Gross Margin %: 35.86% (43% below median its 10-year median of 63.08)
GF Value™: €31.22 vs. price of €70.49 (125.8% above fair value)
Industry Position: 41.1% below the Biotechnology median (#597 of 734)
No single metric tells the full story. See the CHIX:0QFD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
65GF Score
Get the complete analysis for CHIX:0QFD
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:0QFD has been successfully added to your 
